Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer.

Butler SS, Mahal BA, Lamba N, Mossanen M, Martin NE, Mouw KW, Nguyen PL, Muralidhar V.

Cancer. 2019 May 31. doi: 10.1002/cncr.32202. [Epub ahead of print]

PMID:
31150125
2.

Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.

Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.

JAMA Oncol. 2015 Jun;1(3):334-40. doi: 10.1001/jamaoncol.2014.284.

PMID:
26181182
3.

Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.

Yang DD, Muralidhar V, Nguyen PL, Buzurovic I, Martin NE, Mouw KW, Devlin PM, Trinh QD, Orio PF 3rd, King MT.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):904-911. doi: 10.1016/j.ijrobp.2017.07.034. Epub 2017 Jul 31.

PMID:
29063853
4.

Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.

Aizer AA, Chen MH, Hattangadi J, D'Amico AV.

BJU Int. 2014 Jan;113(1):43-50. doi: 10.1111/j.1464-410X.2012.11789.x. Epub 2013 Mar 8.

5.

Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.

Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Orio PF 3rd, King MT, Martin NE, Mouw KW, Trinh QD, Nguyen PL.

Clin Genitourin Cancer. 2018 Jun;16(3):226-234. doi: 10.1016/j.clgc.2017.10.013. Epub 2017 Nov 9.

PMID:
29196209
6.

Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.

Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schröder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1672-7. doi: 10.1111/j.1464-410X.2012.11434.x. Epub 2012 Aug 29.

7.

Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.

Faisal FA, Sundi D, Pierorazio PM, Ball MW, Humphreys EB, Han M, Epstein JI, Partin AW, Carter HB, Bivalacqua TJ, Schaeffer EM, Ross AE.

BJU Int. 2014 Dec;114(6b):E120-E129. doi: 10.1111/bju.12771. Epub 2014 Aug 13.

8.

Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).

Russo AL, Chen MH, Aizer AA, Hattangadi JA, D'Amico AV.

BJU Int. 2012 Oct;110(7):973-9. doi: 10.1111/j.1464-410X.2012.11470.x.

10.

Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.

Morlacco A, Cheville JC, Rangel LJ, Gearman DJ, Karnes RJ.

Eur Urol. 2017 Sep;72(3):442-447. doi: 10.1016/j.eururo.2016.08.043. Epub 2016 Aug 27.

PMID:
27574819
11.

Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.

Keane FK, Chen MH, Zhang D, Moran BJ, Braccioforte MH, D'Amico AV.

Cancer. 2015 Aug 15;121(16):2713-9. doi: 10.1002/cncr.29420. Epub 2015 Apr 29.

12.

External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.

Wang C, Kishan AU, Kamrava M, Steinberg ML, King CR.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1045-1052. doi: 10.1016/j.ijrobp.2017.03.040. Epub 2017 Mar 31.

PMID:
28721887
13.

Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis.

Shao YH, Kim S, Moore DF, Shih W, Lin Y, Stein M, Kim IY, Lu-Yao GL.

Eur Urol. 2014 Apr;65(4):693-700. doi: 10.1016/j.eururo.2013.05.023. Epub 2013 May 21.

14.

Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.

Hattangadi JA, Chen MH, D'Amico AV.

BJU Int. 2012 Dec;110(11):1636-41. doi: 10.1111/j.1464-410X.2012.11354.x. Epub 2012 Jul 3.

15.

The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study.

Matthes KL, Pestoni G, Korol D, Van Hemelrijck M, Rohrmann S.

Urol Oncol. 2018 Jun;36(6):309.e15-309.e23. doi: 10.1016/j.urolonc.2018.02.016. Epub 2018 Mar 22.

PMID:
29576269
16.

Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.

Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, Feng FY, Hoffman KE, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL.

Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):828-35. doi: 10.1016/j.ijrobp.2015.07.2281. Epub 2015 Jul 29.

17.
18.

Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging.

Muralidhar V, Dinh KT, Mahal BA, Ziehr DR, Chen YW, Viswanathan VB, Nezolosky MD, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Trinh QD, Nguyen PL.

Urol Oncol. 2015 Jul;33(7):330.e19-25. doi: 10.1016/j.urolonc.2015.03.010. Epub 2015 May 16.

PMID:
25990612
19.

Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database.

Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ.

Prostate. 2017 Feb;77(2):154-163. doi: 10.1002/pros.23255. Epub 2016 Sep 29.

Supplemental Content

Support Center